Scarica l'app Stockscreener
100.90
0.23%
0.23
Exact Sciences Corp Borsa (EXAS) Ultime notizie
Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover - MSN
Abbott’s (ABT) Exact Sciences Deal is “Very, Very Important,” Says Jim Cramer - Insider Monkey
Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences CorporationEXAS - Barchart.com
Analysts Are Bullish on These Healthcare Stocks: Nano-X Imaging (NNOX), Exact Sciences (EXAS) - The Globe and Mail
Exact Sciences Corp Executives Engage in Stock Transactions - TradingView
[Form 4] EXACT SCIENCES CORP Insider Trading Activity - Stock Titan
VP Orville Sells 5,000 ($375K) Of Exact Sciences Corp [EXAS] - TradingView
Exact Sciences Stock Soars To 4-Year High Even As Wall Street Piles On Downgrades After Abbott Deal — Retail Traders Take Profits - MSN
Exact Sciences likely needs to see over $100/share in takeoveranalyst - MSN
Deal Dispatch: Abbott, TPG And Lonza Make Major Moves, M&M Custard And New Fortress Energy Struggle - Benzinga
Exact Sciences (EXAS): Wells Fargo Downgrades Rating, Raises Pri - GuruFocus
Abbott Laboratories to acquire Exact Sciences for $23B in largest-ever diagnostics deal - The Business Journals
Exact Sciences (EXAS) Receives Downgrade from William Blair | EX - GuruFocus
Abbott Labs stock to acquire Exact Sciences for $21 billion - Investing.com
Abbott Labs stock to acquire Exact Sciences for $21 billion By Investing.com - Investing.com UK
Exact Sciences (EXAS) Downgraded to Neutral by Guggenheim | EXAS Stock News - GuruFocus
EXAS: Barclays Downgrades Exact Sciences, Raises Price Target to $105 | EXAS Stock News - GuruFocus
Here Are Friday’s Top Wall Street Analysts Research Calls: Advanced Micro Devices, Block, Broadcom, Exact Sciences, Hologic, Palo Alto Networks and More - Yahoo Finance
Abbott Labs stock gains as UBS reiterates Buy rating on Exact Sciences deal - Investing.com
Abbott is buying Exact Sciences. Here’s why - Modern Healthcare News
Here Are Friday's Top Wall Street Analysts Research Calls: Advanced Micro Devices, Block, Broadcom, Exact Sciences, Hologic, Palo Alto Networks and More - 24/7 Wall St.
Exact Sciences joins Abbott, shares soar 18% on acquisition and growth prospects - Mugglehead Magazine
Abbott Eyes Exact Sciences: Market Stir - StocksToTrade
Halper Sadeh LLC Encourages CIVI, JAMF, EXAS Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Exact Sciences, Leader in Cancer Screening and Genomics Testing, to Join Abbott Laboratories in 2026 - Morningstar
Why the Stock Price of This Cancer Screening Company Soared 17% Thursday - MSN
Abbott Laboratories $23B purchase of Cologuard maker Exact Sciences could have Arizona implications - The Business Journals
Abbott to Buy Cancer-Screener Exact Sciences for $21 Billion - MSN
Why Exact Sciences Stock Surged Today - Finviz
Abbott Laboratories to acquire Exact Sciences in deal worth up to $23B - The Business Journals
Why Exact Sciences Rallied Over 50% This Week - Nasdaq
Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here? - Yahoo Finance
Abbott Laboratories, Exact Sciences make $23B deal with Bay Area implicationsSan Francisco Business Times - The Business Journals
EXAS Shares Soar Amid Acquisition Rumors - timothysykes.com
Exact Sciences (EXAS) Soars Over 17% in Stock Market Surge - GuruFocus
Watch Abbott to Buy Cancer-Screener Exact Sciences for $21 Billion - Bloomberg.com
Abbott buys Exact Sciences for $21B, marking major cancer diagnostics play - Medical Marketing and Media
Abbott bets on cancer screening with $23 billion Exact Sciences deal - Reuters
Abbott Laboratories to buy Exact Sciences in $23B deal - The Business Journals
Guggenheim Downgrades Exact Sciences (EXAS) to Neutral - StreetInsider
Abbott-Exact Sciences Deal Set to Shake Up Diagnostic Market with Cancer-Fighting Acquisition - inkl
What to know about Exact Sciences. The Madison company was sold to Abbottfor $23 billion. - Milwaukee Journal Sentinel
Abbott makes cancer screening play with $21B Exact Sciences buy - BioWorld MedTech
UBS maintains Exact Sciences stock rating at Neutral amid Abbott acquisition reports - Investing.com
Exact Sciences (EXAS) Shares Surge Nearly 18% - GuruFocus
PR News | Collected Strategies Works Exact Sciences’ DealThu., Nov. 20, 2025 - O'Dwyer's PR
Abbott Laboratories Makes $21 Billion Bet On Cancer Diagnostics - Finimize
Abbott to Buy Cologuard Maker Exact Sciences for $21 Billion - Bloomberg.com
Abbott to Acquire Exact Sciences for $21B - Medical Product Outsourcing
Abbott's $23 Billion Cancer Gambit: Snapping Up Exact Sciences to Revolutionize Diagnostics - WebProNews
Abbott Laboratories to buy Exact Sciences for $21B - Modern Healthcare News
Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics - Benzinga
Abbott to buy Cologuard maker Exact Sciences for $21 billion - Crain's Chicago Business
Exact Sciences stock jumps after Abbott confirms acquisition - Investing.com
Abbott to buy Exact Sciences for $21 billion - breakingthenews.net
Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences - Yahoo! Finance Canada
Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences By Reuters - Investing.com
S&P 500 Futures Rise in Premarket Trading; Exact Sciences, Applied Digital Lead - Barron's
Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments - WV News
Exact Sciences (EXAS) Climbs to 2-Year High on Abbot Merger Reports - Insider Monkey
1.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):